By Scientia Professor Vlado Perkovic

Journal articles

Neuen B; Heerspink H; Neal B; Matthews D; de Zeeuw D; Mahaffey K; Davidson J; Jardine M; Zoungas S; Perkovic V, 2019, 'Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin', Endocrine Practice, 25, pp. 99 - 100, http://dx.doi.org/10.1016/s1530-891x(20)46603-0

Toto R; Perkovic V; Johansen OE; Cooper M; Rosenstock J; Kahn S; Marx N; Alexander JH; George J; Zinman B, 2019, 'Abstract #289 Effect of Linagliptin on Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes and Kidney Disease: Carmelina®', Endocrine Practice, 25, pp. 117 - 118, http://dx.doi.org/10.1016/s1530-891x(20)46633-9

Figtree G; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B, 2019, 'EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE OUTCOMES WITH AND WITHOUT PRESERVED EJECTION FRACTION IN TYPE 2 DIABETES: RESULTS FROM THE CANVAS PROGRAM', Journal of the American College of Cardiology, 73, pp. 685, http://dx.doi.org/10.1016/s0735-1097(19)31293-8

Smyth B; Haber A; Trongtrakul K; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'SAT-041 A META-ANALYSIS OF THE REPRESENTATIVENESS OF RANDOMIZED CONTROLLED TRIAL COHORTS IN END-STAGE KIDNEY DISEASE', Kidney International Reports, 4, pp. S21 - S21, http://dx.doi.org/10.1016/j.ekir.2019.05.064

OSHIMA M; Jun M; Toyama T; Perkovic V; Chalmers J; Woodward M, 2019, 'SAT-287 eGFR SLOPE AND THE SUBSEQUENT RISK OF CLINICAL OUTCOMES IN TYPE 2 DIABETES', Kidney International Reports, 4, pp. S128 - S128, http://dx.doi.org/10.1016/j.ekir.2019.05.325

Toyama T; NEUEN B; Jun M; Ohkuma T; Neal B; Jardine M; Heerspink H; Ninomiya T; Wada T; Perkovic V, 2019, 'SAT-298 EFFECT OF SGLT2 INHIBITORS ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE', Kidney International Reports, 4, pp. s133, http://dx.doi.org/10.1016/j.ekir.2019.05.338

, 2019, 'When should treatment be started for hypertension?', Aust Prescr, 42, pp. 180 - 181, http://dx.doi.org/10.18773/austprescr.2019.069

Mohammedi K; Chalmers J; Herrington W; Li Q; Mancia G; Marre M; Poulter N; Rodgers A; Williams B; Perkovic V; Coresh J; Woodward M, 2018, 'Associations between body mass index and the risk of renal events in patients with type 2 diabetes', Nutrition and Diabetes, 8, pp. 7, http://dx.doi.org/10.1038/s41387-017-0012-y

de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE, 2018, 'Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial', The Lancet Diabetes and Endocrinology, 6, pp. 925 - 933, http://dx.doi.org/10.1016/S2213-8587(18)30289-4

Tong A; Manns B; Wang AYM; Hemmelgarn B; Wheeler DC; Gill J; Tugwell P; Pecoits-Filho R; Crowe S; Harris T; Van Biesen W; Winkelmayer WC; Levin A; Thompson A; Perkovic V; Ju A; Gutman T; Bernier-Jean A; Viecelli AK; O'Lone E; Shen J; Josephson MA; Cho Y; Johnson DW; Sautenet B; Tonelli M; Craig JC; Sinha A; Ong A; Denny A; Dart A; Eddy A; Kelly A; Davenport A; Narva A; Sharma A; Warrens A; Chapman A; Teixeira-Pinto A; Murphy B; Padilla B; Canaud B; Pullin B; Schiller B; Robinson B; Hanson C; Hawley C; Logeman C; Lok C; Wanner C; Herzog C; Rutherford C; Ahn C; Sumpton D; Rosenbloom D; Harris D; Baron D; White D; Gipson D; Fouque D; Eilers D; Bockenhauer D; O'Donoghue D; Chen D; Dunning D; Brown E; Bavlovlenkov E; Mannon E; Poggio E; Chemla E; Dobbels F; Zannad F; Caskey F; Tentori F; Hurst F; Schaefer F; Wong G; Brunier G; Strippoli G; Rangan G; Knoll G; Obrador G; Feldman H; Coolican H; Yap HK; Groothoff J; Sloand J; Tan J; Locke J; Perl J; Chapman J; Dong J; Malyszko J; Fox J; Dapueto J; Tze-Wah Kao J; Chow KM; Manera K; Azukaitis K; Polkinghorne K, 2018, 'Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop', Kidney International, 94, pp. 1053 - 1068, http://dx.doi.org/10.1016/j.kint.2018.08.018

Wong MG; Jardine M; Perkovic V, 2018, 'Glucose lowering and the kidney: are all drug classes equal?', The Lancet Diabetes and Endocrinology, 6, pp. 835 - 837, http://dx.doi.org/10.1016/S2213-8587(18)30291-2

Neuen BL; Perkovic V, 2018, 'Reducing cardiovascular risk in people with diabetes and kidney disease', Medical Journal of Australia, 209, pp. 438 - 439, http://dx.doi.org/10.5694/MJA18.00929

Heerspink HJL; List J; Perkovic V, 2018, 'New clinical trial designs for establishing drug efficacy and safety in a precision medicine era', Diabetes, Obesity and Metabolism, 20, pp. 14 - 18, http://dx.doi.org/10.1111/dom.13417

Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S, 2018, 'Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease', Cochrane Database of Systematic Reviews, 2018, http://dx.doi.org/10.1002/14651858.CD011798.pub2

Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B, 2018, 'Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials', The Lancet Diabetes and Endocrinology, 6, pp. 691 - 704, http://dx.doi.org/10.1016/S2213-8587(18)30141-4

Matthews DR; Perkovic V; Mahaffey KW, 2018, 'Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"', Circulation, 138, pp. 660 - 661, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035717

Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Yi T; Parving HH; de Zeeuw D, 2018, 'Baseline characteristics and enrichment results from the SONAR trial', Diabetes, Obesity and Metabolism, 20, pp. 1829 - 1835, http://dx.doi.org/10.1111/dom.13315

Neuen BL; Ohkuma T; Neal B; Matthews DR; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine M; Bakris G; Perkovic V, 2018, 'Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease', DIABETES, 67, http://dx.doi.org/10.2337/db18-258-OR

Heerspink HJL; Perkovic V, 2018, 'Trial design innovations to accelerate therapeutic advances in chronic kidney disease: Moving from single trials to an ongoing platform', Clinical Journal of the American Society of Nephrology, 13, pp. 946 - 948, http://dx.doi.org/10.2215/CJN.01290118

Rådholm K; Wu JH; Wong MG; Foote C; Fulcher G; Mahaffey KW; Perkovic V; Neal B, 2018, 'Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review', Diabetes Research and Clinical Practice, 140, pp. 118 - 128, http://dx.doi.org/10.1016/j.diabres.2018.03.027

Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D, 2018, 'Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy', Diabetes, Obesity and Metabolism, 20, pp. 1369 - 1376, http://dx.doi.org/10.1111/dom.13245

de Zeeuw D; Heerspink HJL; Jardine M; Perkovic V, 2018, 'Renal trials in diabetes need a platform: time for a global approach?', The Lancet Diabetes and Endocrinology, 6, pp. 356 - 358, http://dx.doi.org/10.1016/S2213-8587(17)30263-2

Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK, 2018, 'Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA^®): A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk', Cardiovascular Diabetology, 17, http://dx.doi.org/10.1186/s12933-018-0682-3

Pecoits-Filho R; Perkovic V, 2018, 'Are SGLT2 inhibitors ready for prime time for CKD?', Clinical Journal of the American Society of Nephrology, 13, pp. 318 - 320, http://dx.doi.org/10.2215/CJN.07680717

Okpechi IG; Alrukhaimi M; Ashuntantang GE; Bellorin-Font E; Benghanem Gharbi M; Braam B; Feehally J; Harris DC; Jha V; Jindal K; Johnson DW; Kalantar-Zadeh K; Kazancioglu R; Levin A; Lunney M; Olanrewaju TO; Perkovic V; Perl J; Rashid HU; Rondeau E; Salako BL; Samimi A; Sola L; Tchokhonelidze I; Wiebe N; Yang CW; Ye F; Zemchenkov A; Zhao MH; Bello AK, 2018, 'Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology', Kidney International Supplements, 8, pp. 82 - 89, http://dx.doi.org/10.1016/j.kisu.2017.10.012

Mahaffey KW; Neal B; Perkovic V; De Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR, 2018, 'Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)', Circulation, 137, pp. 323 - 334, http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038

Wong MG; Heerspink HJL; Perkovic V, 2018, 'ACCORDION: Ensuring that we hear the music clearly', Clinical Journal of the American Society of Nephrology, 13, pp. 1621 - 1623, http://dx.doi.org/10.2215/CJN.11370918

Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; De Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B, 2018, 'Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS program', Circulation, 138, pp. 458 - 468, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222

Neuen BL; Ohkuma T; Neal B; Matthews DR; De Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V, 2018, 'Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program', Circulation, 138, pp. 1537 - 1550, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901

Jun M; Ohkuma T; Zoungas S; Colagiuri S; Mancia G; Marre M; Matthews D; Poulter N; Williams B; Rodgers A; Perkovic V; Chalmers J; Woodward M, 2018, 'Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON', Diabetes Care, 41, pp. 163 - 170, http://dx.doi.org/10.2337/dc17-1467

Smyth B; Perkovic V, 2018, 'New hypoglycemic agents and the kidney: What do the major trials tell us?.', F1000Research, 7, http://dx.doi.org/10.12688/f1000research.16135.1

Jardine MJ; Mahaffey KW; Neal B; Agarwal R; Bakris GL; Brenner BM; Bull S; Cannon CP; Charytan DM; De Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Pollock C; Wheeler DC; Xie J; Zhang H; Zinman B; Desai M; Perkovic V, 2018, 'The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics', American Journal of Nephrology, 46, pp. 462 - 472, http://dx.doi.org/10.1159/000484633

Ovalle F; Dumas R; Fabbrini E; Slee A; Perkovic V, 2018, 'Abstract #233 Outcomes with Canagliflozin in Patients By Age Subgroups: Results from the Canvas Program', Endocrine Practice, 24, pp. 45 - 45, http://dx.doi.org/10.1016/s1530-891x(20)47079-x

Neal B; Perkovic V; Matthews DR, 2017, 'Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Reply', NEW ENGLAND JOURNAL OF MEDICINE, 377, pp. 2099 - 2099

Neal B; Perkovic V; Matthews DR, 2017, 'The authors reply', New England Journal of Medicine, 377, pp. 2099, http://dx.doi.org/10.1056/NEJMc1712572

Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M, 2017, 'Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial', Diabetes, Obesity and Metabolism, 19, pp. 1610 - 1619, http://dx.doi.org/10.1111/dom.13041

Levin A; Tonelli M; Bonventre J; Coresh J; Donner JA; Fogo AB; Fox CS; Gansevoort RT; Heerspink HJL; Jardine M; Kasiske B; Köttgen A; Kretzler M; Levey AS; Luyckx VA; Mehta R; Moe O; Obrador G; Pannu N; Parikh CR; Perkovic V; Pollock C; Stenvinkel P; Tuttle KR; Wheeler DC; Eckardt KU; Adu D; Agarwal SK; Alrukhaimi M; Anders HJ; Ashuntantang G; Basnet S; Bello AK; Chailimpamontree W; Correa-Rotter R; Craig J; Douthat WG; Feldman HI; Ganji MR; Garcia-Garcia G; Gharbi MB; Harris DC; Jha V; Johnson DW; Kazancioglu R; Langham R; Liu ZH; Massy ZA; Nangaku M; Nelson RG; O'Donoghue D; Okpechi I; Pecoits-Filho R; Powe NR; Remuzzi G; Roberts C; Rossert J; Sola L; Stengel B; M EKS; Suzuki Y; Tanaka T; Tatiyanupanwong S; Thomas B; Uhlig K; Walker R; White SL; Wiecek A; Yang CW, 2017, 'Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy', The Lancet, 390, pp. 1888 - 1917, http://dx.doi.org/10.1016/S0140-6736(17)30788-2

Perkovic V; Craig JC; Chailimpamontree W; Fox CS; Garcia-Garcia G; Benghanem Gharbi M; Jardine MJ; Okpechi IG; Pannu N; Stengel B; Tuttle KR; Uhlig K; Levey AS, 2017, 'Action plan for optimizing the design of clinical trials in chronic kidney disease', Kidney International Supplements, 7, pp. 138 - 144, http://dx.doi.org/10.1016/j.kisu.2017.07.009

Jardine MJ; Kasiske B; Adu D; Alrukhaimi M; Ashuntantang GE; Basnet S; Chailimpamontree W; Craig JC; O'Donoghue DJ; Perkovic V; Powe NR; Roberts CJ; Suzuki Y; Tanaka T; Uhlig K, 2017, 'Closing the gap between evidence and practice in chronic kidney disease', Kidney International Supplements, 7, pp. 114 - 121, http://dx.doi.org/10.1016/j.kisu.2017.07.006

Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D, 2017, 'Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis', PLoS ONE, 12, pp. e0184398, http://dx.doi.org/10.1371/journal.pone.0184398

Marx N; McGuire DK; Perkovic V; Woerle HJ; Broedl UC; Von Eynatten M; George JT; Rosenstock J, 2017, 'Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?', Diabetes Care, 40, pp. 1144 - 1151, http://dx.doi.org/10.2337/dc17-0068

Webb DJ; Coll B; Heerspink HJL; Andress D; Pritchett Y; Brennan JJ; Houser M; Correa-Rotter R; Kohan D; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Busch R; Pergola P; Parving HH; de Zeeuw D, 2017, 'Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial', Drugs in R and D, 17, pp. 441 - 448, http://dx.doi.org/10.1007/s40268-017-0201-0

Matsushita K; Ballew SH; Coresh J; Arima H; Ärnlöv J; Cirillo M; Ebert N; Hiramoto JS; Kimm H; Shlipak MG; Visseren FLJ; Gansevoort RT; Kovesdy CP; Shalev V; Woodward M; Kronenberg F; Chalmers J; Perkovic V; Grams ME; Sang Y; Schaeffner E; Martus P; Levin A; Djurdjev O; Tang M; Heine G; Seiler S; Zawada A; Emrich I; Sarnak M; Katz R; Brenner H; Schöttker B; Rothenbacher D; Saum KU; Köttgen A; Schneider M; Eckardt KU; Green J; Kirchner HL; Chang AR; Black C; Marks A; Prescott G; Clark L; Fluck N; Jee SH; Mok Y; Chodick G; Wetzels JFM; Blankestijn PJ; van Zuilen AD; Bots M; Peralta C; Hiromoto J; Bottinger E; Nadkarni GN; Ellis SB; Nadukuru R; Kenealy T; Elley CR; Collins JF; Drury PL; Bakker SJ; Heerspink HJL; Jassal SK; Bergstrom J; Ix JH; Barrett-Connor E; Kalantar-Zadeh K; Carrero JJ; Gasparini A; Qureshi AR; Barany P; Algra A; van der Graaf Y; Evans M; Segelmark M; Stendahl M; Schön S; Tangri N; Sud M; Naimark D; Lannfelt L; Larsson A; Hallan S; Levey AS; Chen J; Kwak L, 2017, 'Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data', The Lancet Diabetes and Endocrinology, 5, pp. 718 - 728, http://dx.doi.org/10.1016/S2213-8587(17)30183-3

Neal B; Perkovic V; Mahaffey KW; De Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR, 2017, 'Canagliflozin and cardiovascular and renal events in type 2 diabetes', New England Journal of Medicine, 377, pp. 644 - 657, http://dx.doi.org/10.1056/NEJMoa1611925

Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V, 2017, 'Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial', JAMA - Journal of the American Medical Association, 318, pp. 432 - 442, http://dx.doi.org/10.1001/jama.2017.9362

Patel A; Pieper K; Myburgh JA; Perkovic V; Finfer S; Yang Q; Li Q; Billot L, 2017, 'Reanalysis of the crystalloid versus hydroxyethyl starch trial (CHEST)', New England Journal of Medicine, 377, pp. 298 - 300, http://dx.doi.org/10.1056/NEJMc1703337

Yu J; Zhou Z; McEvoy RD; Anderson CS; Rodgers A; Perkovic V; Neal B, 2017, 'Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: A systematic review and meta-analysis', JAMA - Journal of the American Medical Association, 318, pp. 156 - 166, http://dx.doi.org/10.1001/jama.2017.7967

Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P, 2017, 'Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial', Nephrology, 22, pp. 548 - 554, http://dx.doi.org/10.1111/nep.12815

Neal B; Perkovic V; Mahaffey KW; Fulcher G; Erondu N; Desai M; Shaw W; Law G; Walton MK; Rosenthal N; de Zeeuw D; Matthews DR, 2017, 'Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials', Diabetes, Obesity and Metabolism, 19, pp. 926 - 935, http://dx.doi.org/10.1111/dom.12924

Jardine MJ; Zuo L; Gray NA; De Zoysa JR; Chan CT; Gallagher MP; Monaghan H; Grieve SM; Puranik R; Lin H; Eris JM; Zhang L; Xu J; Howard K; Lo S; Cass A; Perkovic V, 2017, 'A trial of extending hemodialysis hours and quality of life', Journal of the American Society of Nephrology, 28, pp. 1898 - 1911, http://dx.doi.org/10.1681/ASN.2015111225

Back to profile page